These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32172728)

  • 1. Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective.
    Cho J
    BMB Rep; 2020 Mar; 53(3):133-141. PubMed ID: 32172728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
    Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
    Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
    Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
    Park AK; Francis JM; Park WY; Park JO; Cho J
    Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
    Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
    Gordon-Thomson C; Jones J; Mason RS; Moore GP
    Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
    Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
    Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation.
    Kancha RK; von Bubnoff N; Duyster J
    Cell Commun Signal; 2013 Jun; 11():39. PubMed ID: 23758840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
    Sheng Q; Liu J
    Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.